ICU Medical IncICUI
▲ PositiveCapitalrelevance
Q2 earnings and EPS beat estimates, and full-year guidance raised.
Impact on stocks 1
Health Care
ICU Medical IncICU Medical Q2 Earnings Beat Estimates on Infusion Systems Strength
Earnings
ICU Medical reported second quarter results that beat analyst expectations, driven by strong performance in its Infusion Systems and Consumables segments. Revenue came in at $547.9 million versus estimates of $532.8 million, while adjusted EPS of $2.37 beat the $1.91 consensus by 23.8%. The company also raised its full-year adjusted EPS guidance to $8.80 at the midpoint, above analyst estimates by 7.8%. During the earnings call, analysts questioned management about the durability of growth, with CEO Vivek Jain attributing Infusion Systems strength to competitive wins and earlier installations rather than a broader replacement cycle, and noting that organic growth should continue at or above a 6% rate.
ICU Medical IncQ2 earnings and EPS beat estimates, and full-year guidance raised.